Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1099-1111

  Lopez Ayllon, Blanca D ^a   Moncho Amor, Veronica ^a   Abarrategi, Ander ^b   de Cáceres, Inmaculada Ibañez ^c   Castro Carpeño, Javier ^c   Belda Iniesta, Cristobal ^d   Perona, Rosario ^a,e   Sastre, Leandro ^a,e  

^a INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Hospital Madrid Norte Sanchinarro   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

Author keywords

Cancer stem cells; Cancer initiating cells; Cisplatin resistance; Lung cancer; NSCLC

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; EARLY GROWTH RESPONSE FACTOR 1; ANTINEOPLASTIC AGENT;

ADM GENE; AKAP12 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER CELL LINE; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INTERACTION; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; COX2 GENE; DRUG SENSITIVITY; EGR1 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALAT1 GENE; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENETICS; LUNG TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; TUMOR STEM CELL ASSAY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR STEM CELL ASSAY;

EID: 84991442356     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.291     Document Type: Article

References (49)

1. Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127:2893-2917.
2. Kelsey, C. R., L. B. Marks, D. Hollis, J. L. Hubbs, N. E. Ready, T. A. D'Amico, et al. 2009. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 115:5218-5227.
3. Reya, T., S. J. Morrison, M. F. Clarke, and I. L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
4. Morrison, B. J., J. C. Morris, and J. C. Steel. 2013. Lung cancer-initiating cells: a novel target for cancer therapy. Target Oncol 8:159-172.
5. Alamgeer, M., C. D. Peacock, W. Matsui, V. Ganju, and D. N. Watkins. 2013. Cancer stem cells in lung cancer: evidence and controversies. Respirology 18:757-764.
6. Chattopadhyay, S., R. Machado-Pinilla, C. Manguan-Garcia, C. Belda-Iniesta, C. Moratilla, P. Cejas, et al. 2006. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25:3335-3345.
7. Galluzzi, L., L. Senovilla, I. Vitale, J. Michels, I. Martins, O. Kepp, et al. 2012. Molecular mechanisms of cisplatin resistance. Oncogene 31:1869-1883.
8. Shen, D. W., L. M. Pouliot, M. D. Hall, and M. M. Gottesman. 2012. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64:706-721.
9. Zhang, Y. W., L. M. Wang, R. Jove, and G. F. Vande Woude. 2002. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21:217-226.
10. Moncho-Amor, V., I. Ibanez de Caceres, E. Bandres, B. Martinez-Poveda, J. L. Orgaz, I. Sanchez-Perez, et al. 2011. DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene 30:668-678.
11. Espina, C., M. V. Cespedes, M. A. Garcia-Cabezas, M. T. Gomez del Pulgar, A. Boluda, L. G. Oroz, et al. 2008. A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells. Am. J. Pathol. 172:156-166.
12. Breitling, R., P. Armengaud, A. Amtmann, and P. Herzyk. 2004. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573:83-92.
13. Oliveros, J. 2007. FIESTA at BioinfoCP. An interactive server for analyzing DNA microarray experiments with replicates. Available at http://bioinfogp.cnb.csic.es/tools/FIESTA (accessed February 7, 2011).
14. Oliveros, J. 2007. VENNY. An interactive tool for comparing lists with Venn Diagrams. Available at http://bioinfogp.cnb.csic.es/tools/venny/index.html (accessed February 7, 2011).
15. Ashburner, M., C. A. Ball, J. A. Blake, D. Botstein, H. Butler, J. M. Cherry, et al. 2000. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat. Genet. 25:25-29.
16. Giulietti, A., L. Overbergh, D. Valckx, B. Decallonne, R. Bouillon, and C. Mathieu. 2001. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 25:386-401.
17. Sanchez-Perez, I., J. R. Murguia, and R. Perona. 1998. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16:533-540.
18. Levina, V., A. Marrangoni, R. DeMarco, E. Gorelik, and A. Lokshin. 2008. Drug-selected human lung cancer stem cells: cytokine network. Tumorigenic and metastatic properties. PLoS ONE 3:e3077.
19. Lundholm, L., P. Haag, D. Zong, T. Juntti, B. Mork, R. Lewensohn, et al. 2013. Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest. Cell Death Dis. 4:e478.
20. Wang, P., Q. Gao, Z. Suo, E. Munthe, S. Solberg, L. Ma, et al. 2013. Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS ONE 8:e57020.
21. Giarnieri, E., C. De Vitis, A. Noto, G. Roscilli, G. Salerno, S. Mariotta, et al. 2013. EMT markers in lung adenocarcinoma pleural effusion spheroid cells. J. Cell. Physiol. 228:1720-1726.
22. Bertolini, G., L. Roz, P. Perego, M. Tortoreto, E. Fontanella, L. Gatti, et al. 2009. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl Acad. Sci. USA 106:16281-16286.
23. Ho, M. M., A. V. Ng, S. Lam, and J. Y. Hung. 2007. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 67:4827-4833.
24. Morrison, B. J., J. C. Steel, and J. C. Morris. 2012. Sphere culture of murine lung cancer cell lines are enriched with cancer initiating cells. PLoS ONE 7:e49752.
25. Kreso, A., C. A. O'Brien, P. van Galen, O. I. Gan, F. Notta, A. M. Brown, et al. 2013. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339:543-548.
26. Sugiura, H., K. Yamada, T. Sugiura, T. Hida, and T. Mitsudomi. 2008. Predictors of survival in patients with bone metastasis of lung cancer. Clin. Orthop. Relat. Res. 466:729-736.
27. Miller, T. T. 2008. Bone tumors and tumorlike conditions: analysis with conventional radiography. Radiology 246:662-674.
28. Vicent, S., D. Luis-Ravelo, I. Anton, I. Garcia-Tunon, F. Borras-Cuesta, J. Dotor, et al. 2008. A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res. 68:2275-2285.
29. Akakura, S., and I. H. Gelman. 2012. Pivotal role of AKAP12 in the regulation of cellular adhesion dynamics: control of cytoskeletal architecture, cell migration, and mitogenic signaling. J. Signal. Transduct. 2012:529179.
30. Chappell, N. P., P. N. Teng, B. L. Hood, G. Wang, K. M. Darcy, C. A. Hamilton, et al. 2012. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J. Proteome Res. 11:4605-4614.
31. Dong, Q., J. Zhang, D. T. Hendricks, and X. Zhao. 2011. GRObeta and its downstream effector EGR1 regulate cisplatin-induced apoptosis in WHCO1 cells. Oncol. Rep. 25:1031-1037.
32. Khuri, F. R., H. Wu, J. J. Lee, B. L. Kemp, R. Lotan, S. M. Lippman, et al. 2001. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res. 7:861-867.
33. Pasini, A., G. Paganelli, A. Tesei, W. Zoli, E. Giordano, and D. Calistri. 2012. Specific biomarkers are associated with docetaxeland gemcitabine-resistant NSCLC cell lines. Transl. Oncol. 5:461-468.
34. Tano, K., R. Mizuno, T. Okada, R. Rakwal, J. Shibato, Y. Masuo, et al. 2010. MALAT-1 enhances cell motility of lung adenocarcinoma cells by influencing the expression of motility-related genes. FEBS Lett. 584:4575-4580.
35. Zudaire, E., A. Martinez, and F. Cuttitta. 2003. Adrenomedullin and cancer. Regul. Pept. 112:175-183.
36. Kane, S., M. A. Prentice, J. M. Mariano, F. Cuttitta, and S. B. Jakowlew. 2002. Differential induction of early response genes by adrenomedullin and transforming growth factor-beta1 in human lung cancer cells. Anticancer Res. 22:1433-1444.
37. Nikitenko, L. L., S. B. Fox, S. Kehoe, M. C. Rees, and R. Bicknell. 2006. Adrenomedullin and tumour angiogenesis. Br. J. Cancer 94:1-7.
38. Martey, C. A., C. J. Baglole, T. A. Gasiewicz, P. J. Sime, and R. P. Phipps. 2005. The aryl hydrocarbon receptor is a regulator of cigarette smoke induction of the cyclooxygenase and prostaglandin pathways in human lung fibroblasts. Am. J. Physiol. Lung Cell. Mol. Physiol. 289:L391-L399.
39. Portal-Nunez, S., U. T. Shankavaram, M. Rao, N. Datrice, S. Atay, M. Aparicio, et al. 2012. Aryl hydrocarbon receptor-induced adrenomedullin mediates cigarette smoke carcinogenicity in humans and mice. Cancer Res. 72:5790-5800.
40. Liekens, S., D. Schols, and S. Hatse. 2010. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr. Pharm. Des. 16:3903-3920.
41. Jung, M. J., J. K. Rho, Y. M. Kim, J. E. Jung, Y. B. Jin, Y. G. Ko, et al. 2011. Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32:209-221.
42. Burger, J. A., D. J. Stewart, O. Wald, and A. Peled. 2011. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Rev. Anticancer Ther. 11:621-630.
43. Peinado, H., M. Del Carmen Iglesias-de la Cruz, D. Olmeda, K. Csiszar, K. S. Fong, S. Vega, et al. 2005. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. EMBO J. 24:3446-3458.
44. Mohammed Ael, S., H. Eguchi, S. Wada, N. Koyama, M. Shimizu, K. Otani, et al. 2012. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells. Exp. Lung Res. 38:463-474.
45. Yoshino, H., Y. Endo, Y. Watanabe, and T. Sasaki. 1998. Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br. J. Cancer 78:833-839.
46. Pedersen, M. O., A. Larsen, M. Stoltenberg, and M. Penkowa. 2009. The role of metallothionein in oncogenesis and cancer prognosis. Prog. Histochem. Cytochem. 44:29-64.
47. Saga, Y., M. Ohwada, M. Suzuki, R. Konno, J. Kigawa, S. Ueno, et al. 2008. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol. Rep. 20:1299-1303.
48. Akunuru, S., Q. James Zhai, and Y. Zheng. 2012. Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis. 3:e352.
49. Celia-Terrassa, T., O. Meca-Cortes, F. Mateo, A. M. de Paz, N. Rubio, A. Arnal-Estape, et al. 2012. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Invest. 122:1849-1868.